Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 11, 2021, the Board of Directors of ABIOMED, Inc. (the "Company")
appointed Dr. Myron L. Rolle as a Class II director, effective as of February
17, 2021. Dr. Rolle will serve for a term expiring at the Company's 2021 annual
meeting of stockholders. Dr. Rolle has been appointed to the Governance and
Nominating Committee and the Regulatory and Compliance Committee of the Board of
Directors. In connection with Dr. Rolle's appointment, the size of the Company's
Board of Directors was increased to eight directors.
In connection with his service as a non-employee director, Dr. Rolle will
receive compensation in accordance with the Company's current director
compensation program described in the Company's most recently filed proxy
statement with the Securities and Exchange Commission on June 30, 2020.
There are no arrangements or understandings between Dr. Rolle and any other
person pursuant to which Dr. Rolle was elected as a director. There are no
transactions involving Dr. Rolle requiring disclosure under Item 404(a) of
Regulation S-K.
Item 7.01 Regulation FD Disclosure.
On February 17, 2021, the Company issued a press release announcing the
appointment of Dr. Rolle to the Board of Directors. A copy of the press release
is attached as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Description
99.1 Press release dated February 17, 2021
--------------------------------------------------------------------------------
Exhibit Index
Exhibit Description
99.1 Press release dated February 17, 2021
104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ABIOMED, INC. 
